Eli Lilly shares rose 0.4% premarket after reports said the company will move its 50,000 employees’ drug benefits from CVS Caremark to fintech PBM Rightway starting January 1. The move follows CVS’s decision to drop Lilly’s Zepbound in favor of Novo Nordisk’s Wegovy. Retail traders framed the move as a major pushback against PBM power.